NATICK, Mass. – February 6, 2012 – Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that Giora Weisz, M.D., Director of Clinical Cardiovascular Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Associate Professor of medicine at Columbia University College of Physicians and Surgeons, New York, N.Y. will present his personal experience using the CorPath® 200 System as part of the CorPath PRECISE Trial during a scientific presentation "Cath Lab of the Future: Robotics" at the Cardiovascular Research Technologies' annual meeting, CRT2012. The scientific presentation will take place on Tuesday, February 7 at 2:55 p.m. in the Palladian Ballroom at the Omni Shoreham Hotel in Washington, D.C.
"Since the early days when Andreas Grüntzig's delivered his first balloon, not much has changed in the technique we use to perform coronary percutaneous procedures," said Dr. Weisz. "For the first time in my career, I am able to perform interventions without the strain of a heavy lead apron. Using the CorPath 200 System, I am able to perform percutaneous coronary interventions (PCI) procedures precisely and effectively, while sitting comfortably in a radiation protected interventional cockpit. The technology has the potential to change the standard of care and revolutionize the way we perform PCI procedures."
Corindus Vascular Robotics will also host hands-on demonstrations of the CorPath 200 System at booth 505. To reserve your booth presentation of the CorPath 200 System, please call 508.653.3335 x200 or email email@example.com.
As noted in a recent article published in in the Journal of Cardiovascular Translational Research, "Robotic-Assisted Percutaneous Coronary Intervention—Filling an Unmet Need" by Joseph P. Carrozza, M.D., Professor of Medicine at Tufts University School of Medicine, Vice President of Cardiovascular Medicine at Steward Healthcare Systems, Chief of Cardiovascular Medicine at St. Elizabeth's Medical Center, the cumulative exposure to ionizing radiation, orthopedic injuries resulting from lead aprons, and fatigue from standing for hours during the procedure, makes the catheterization laboratory a "high-risk workplace" for the interventional cardiologist. In fact, data published in the Catheterization and Cardiovascular Intervention journal, an interventional cardiologist's daily exposure to radiation and the physical stresses inherent in the cath lab can lead to occupational health risks including orthopedic problems, cataracts and cancer.
The CorPath 200 System allows for controlled robotic-assisted placement of coronary guidewires and stent/balloon catheters from an ergonomically optimized interventional cockpit. The lead-lined cockpit protects the operator from radiation exposure. The comfortable seated position in front of the cockpit monitors provides enhanced visualization of the angiography screen while reducing fatigue and minimizes head, neck and back strain.
"The interest in the interventional cardiology community continues to reinforce the value of the robotic-assisted PCI," said David M. Handler, President and CEO of Corindus. "We are excited with the positive experience the physicians have had so far using the CorPath 200 System during the PRECISE trial."
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: